Assessment of Methadone Clinic Staff Attitudes Toward Hepatitis C Evaluation and Treatment

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2012 Mar 13

PMID 22405884

Citations 6

Authors

Andrew H Talal

Rositsa B Dimova

Randy Seewald

Raymond H Peterson

Marija Zeremski

David C Perlman

Don C Des Jarlais

Affiliations

Soon will be listed here.

Abstract

We used a 25-item, self-administered questionnaire to assess staff's perceived barriers and willingness to engage in onsite treatment of hepatitis C virus (HCV) at the Beth Israel Medical Center methadone maintenance treatment program (MMTP) at its Harlem sites. Of 80 participants, 50% were counselors and 24% were directly involved in referral or HCV testing. Although 92% of the MMTP staff indicated that they discuss HCV evaluation and treatment with patients at least annually, 70% believed that less than 25% of patients accept referral for HCV treatment and attend their initial appointment. Most staff (66%) supported onsite HCV evaluation and treatment, although support was higher among those with a bachelor's degree or higher (p = 0.046). Lack of infrastructure was perceived as the greatest obstacle to onsite treatment. Educational interventions and skill building for staff to confidently engage and support MMTP patients in HCV treatment may be necessary prerequisites for onsite HCV management in MMTPs.

Citing Articles

Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.

Talal A, George S, Talal L, Dharia A, Ventuneac A, Baciewicz G Res Involv Engagem. 2023; 9(1):63.

PMID: 37533127 PMC: 10399008. DOI: 10.1186/s40900-023-00474-x.

Multi-level implementation factors that influence scale-up of methadone maintenance treatment in Moldovan prisons: A qualitative study.

OHara G, Liberman A, Polonsky M, Azbel L, Marcus R, Doltu S J Subst Abuse Treat. 2021; 136:108660.

PMID: 34801282 PMC: 10879837. DOI: 10.1016/j.jsat.2021.108660.

CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.

Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson A MMWR Recomm Rep. 2020; 69(2):1-17.

PMID: 32271723 PMC: 7147910. DOI: 10.15585/mmwr.rr6902a1.

Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Norton B, Akiyama M, Zamor P, Litwin A Infect Dis Clin North Am. 2018; 32(2):347-370.

PMID: 29778260 PMC: 6022838. DOI: 10.1016/j.idc.2018.02.001.

The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.

Bojko M, Mazhnaya A, Marcus R, Makarenko I, Islam Z, Filippovych S J Subst Abuse Treat. 2016; 66:37-47.

PMID: 27211995 PMC: 4919997. DOI: 10.1016/j.jsat.2016.03.003.

References

Hagan H, McGough J, Thiede H, Weiss N, Hopkins S, ALEXANDER E . Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999; 149(3):203-13. DOI: 10.1093/oxfordjournals.aje.a009792. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Brown L, Kritz S, Muhammad A, Bini E, Goldsmith R, Robinson J . Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs. J Addict Med. 2010; 3(2):95-102. PMC: 2743506. DOI: 10.1097/ADM.0b013e318190f0e7. View

Grebely J, Genoway K, Raffa J, Dhadwal G, Rajan T, Showler G . Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2007; 93(1-2):141-7. DOI: 10.1016/j.drugalcdep.2007.09.008. View

Bini E, Kritz S, Brown Jr L, Robinson J, Alderson D, Rotrosen J . Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis. 2011; 30(2):98-109. PMC: 3102428. DOI: 10.1080/10550887.2011.554780. View

Strauss S, Astone-Twerell J, Munoz-Plaza C, Des Jarlais D, Gwadz M, Hagan H . Hepatitis C knowledge among staff in U.S. drug treatment programs. J Drug Educ. 2006; 36(2):141-58. DOI: 10.2190/3EMQ-N350-W4XN-WT1X. View

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

Stephenson J . Former addicts face barriers to treatment for HCV. JAMA. 2001; 285(8):1003-5. DOI: 10.1001/jama.285.8.1003. View

Martinez A, Dimova R, Marks K, Beeder A, Zeremski M, Kreek M . Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat. 2010; 19(1):47-54. PMC: 3708453. DOI: 10.1111/j.1365-2893.2010.01411.x. View

10.

Mehta S, Genberg B, Astemborski J, Kavasery R, Kirk G, Vlahov D . Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008; 33(3):126-33. PMC: 3800027. DOI: 10.1007/s10900-007-9083-3. View

11.

Tseng F, OBrien T, Zhang M, Kral A, Ortiz-Conde B, Lorvick J . Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007; 46(3):666-71. PMC: 4751875. DOI: 10.1002/hep.21765. View

12.

Morrill J, Shrestha M, Grant R . Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005; 20(8):754-8. PMC: 1490173. DOI: 10.1111/j.1525-1497.2005.0161.x. View

13.

Strathdee S, Latka M, Campbell J, ODriscoll P, Golub E, Kapadia F . Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005; 40 Suppl 5:S304-12. PMC: 2196220. DOI: 10.1086/427445. View

14.

Strauss S, Astone-Twerell J, Munoz-Plaza C, Des Jarlais D, Gwadz M, Hagan H . Correlates of drug treatment program staff's self efficacy to support their clients' hepatitis C virus (HCV) related needs. Am J Drug Alcohol Abuse. 2007; 33(2):245-51. DOI: 10.1080/00952990601174899. View

15.

Treloar C, Newland J, Rance J, Hopwood M . Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010; 17(12):839-44. DOI: 10.1111/j.1365-2893.2009.01250.x. View

16.

Volk M, Tocco R, Saini S, Lok A . Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009; 50(6):1750-5. DOI: 10.1002/hep.23220. View

17.

Davis G, Alter M, El-Serag H, Poynard T, Jennings L . Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2009; 138(2):513-21, 521.e1-6. DOI: 10.1053/j.gastro.2009.09.067. View

18.

Thomas D, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R . Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995; 74(4):212-20. DOI: 10.1097/00005792-199507000-00005. View

19.

Tracy K, Brown L, Kritz S, Alderson D, Robinson J, Bini E . Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis. 2009; 28(1):8-12. PMC: 3102438. DOI: 10.1080/10550880802544625. View

20.

Munoz-Plaza C, Strauss S, Astone-Twerell J, Des Jarlais D, Gwadz M, Hagan H . Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy. 2008; 19(1):71-8. PMC: 2698452. DOI: 10.1016/j.drugpo.2007.02.003. View